Showing 1001-1010 of 1211 results for "".
- In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streakshttps://modernod.com/news/in-japanese-study-vabysmo-achieves-primary-endpoint-in-phase-3-study-for-angioid-streaks/2482231/Japan-based Chugai Pharmaceutical announced that the Japanese phase 3 study (NIHONBASHI study), evaluating Roche and Genentech's Vabysmo (faricimab) for angioid streaks associated with neovascularization, met its primary endpoint, demonstrating statistically signific
- Opus Genetics Completes Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-completes-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-lca5/2482180/Opus Genetics announced that the first cohort has completed dosing in its open-label, dose-escalation phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the oute
- Survey: Communications Adjustments Could Supercharge Contact Lens Adoptionhttps://modernod.com/news/survey-communications-adjustments-could-supercharge-contact-lens-adoption/2482164/Simple adjustments to how eye care practices communicate with patients may attract a significantly higher number of contact lens wearers, according to new data from the Contact Lens Institute (CLI). The industry association is previewing its latest
- Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisorhttps://modernod.com/news/opthea-appoints-arshad-m-khanani-md-ma-fasrs-as-chief-medical-advisor/2482120/Opthea announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani is a managing partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, and Clinic
- Researchers Identify Genes and Cell Types That May Have Causal Role in POAG Formationhttps://modernod.com/news/researchers-identify-genes-and-cell-types-that-may-have-causal-role-in-poag-formation/2482119/In a new study published in Nature Communications, researchers from Mass Eye and Ear conducted a comprehensive study that combined genetic discoveries from a large cross-ancestry genome-wide association study meta-analysis of primary open-angle glaucoma (POAG), and a large
- Nicox Announces Presentations at the Upcoming ARVO Annual Meeting 2024https://modernod.com/news/nicox-announces-presentations-at-the-upcoming-arvo-annual-meeting-2024/2482100/Nicox SA announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 5-9, 2024 in Seattle. Abstract/Presentation Title: Tolerability and intraocular pressure (IOP)-lowering efficacy
- EssilorLuxottica Showcases Nuance Audio Smart Eyewear With Hearing-Aid Solutionhttps://modernod.com/news/essilorluxottica-showcases-nuance-audio-smart-eyewear-with-hearing-aid-solution/2482051/EssilorLuxottica announced it will showcase its consumer technology at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada. The company is a France-based designer, manufacturer, and global distributor of eyecare and eyewear prod
- OrCam Unveils Enhancements for MyEye and Read3 Devices at CEShttps://modernod.com/news/orcam-unveils-enhancements-for-myeye-and-read3-devices-at-ces/2482050/OrCam Technologies, which is focused on personal artificial intelligence (AI) assistive technology platforms, introduced new enhancements for its MyEye and Read3 devices at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada.
- Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-patients-with-lca1/2481991/Atsena Therapeutics announced positive 12-month safety and efficacy data from the ongoing phase 1/2 trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 ha
- Signs of Glaucoma May Be Detectable Years in Advance of Disease Onsethttps://modernod.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma. The findings are based on nearly 400 women wh